Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 105.15M P/E - EPS this Y 133.30% Ern Qtrly Grth -
Income -9.53M Forward P/E -2.05 EPS next Y -257.10% 50D Avg Chg -
Sales 42.72M PEG - EPS past 5Y - 200D Avg Chg 28.00%
Dividend N/A Price/Book 1.44 EPS next 5Y - 52W High Chg -29.00%
Recommedations 1.30 Quick Ratio 4.11 Shares Outstanding 89.54M 52W Low Chg 125.00%
Insider Own 5.38% ROA -3.04% Shares Float 84.70M Beta 2.65
Inst Own 15.05% ROE -15.84% Shares Shorted/Prior 1.88M/1.73M Price 1.15
Gross Margin 86.76% Profit Margin -22.31% Avg. Volume 498,775 Target Price 5.00
Oper. Margin -50.91% Earnings Date Nov 5 Volume 254,658 Change -3.36%
About Compugen Ltd.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Ltd. News
11/15/24 Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
11/13/24 Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ...
11/12/24 Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates
11/12/24 Compugen: Q3 Earnings Snapshot
11/12/24 Compugen Reports Third Quarter 2024 Results
11/11/24 Compugen to Participate in Stifel 2024 Healthcare Conference
11/05/24 Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024
10/29/24 Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/24/24 Compugen Gears Up to Report Q3 Earnings: Here's What to Expect
10/07/24 Compugen to Present New Clinical Data at SITC 2024
09/11/24 Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
09/09/24 Compugen to Present at Single Cell Genomics 2024 Conference
08/29/24 Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/26/24 Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
08/11/24 Party Time: Brokers Just Made Major Increases To Their Compugen Ltd. (NASDAQ:CGEN) Earnings Forecasts
08/07/24 Compugen Ltd. (NASDAQ:CGEN): When Will It Breakeven?
08/06/24 Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
08/06/24 Compugen: Q2 Earnings Snapshot
08/06/24 Compugen Reports Second Quarter 2024 Results
07/30/24 Compugen receives FDA approval for Phase I trial of solid tumour treatment
CGEN Chatroom

User Image DirkInvest Posted - 2 days ago

$CGEN Bought some more and keep doing so when it keeps dropping. Lets hope I'm not wrong here :) Hoping for $3-5 or more in about 1-2 years.

User Image Stayinvest Posted - 3 days ago

$CGEN sorry I posted the last to wrong stock

User Image Stayinvest Posted - 3 days ago

$CGEN but still can see you

User Image Stayinvest Posted - 3 days ago

$CGEN no because you blocked on one of those moments that you have that blocked everyone 🤣

User Image Stayinvest Posted - 3 days ago

$CGEN people we need to give support to each other. Barely 4 investors here. I hope we are right at the end of the tunnel

User Image HuntingBenjmins Posted - 5 days ago

$CGEN

User Image Otus Posted - 1 week ago

$CGEN made some fairly significant buys today. Closing in on 200,000 shares.

User Image RachelGreene1 Posted - 1 week ago

$CGEN https://www.youtube.com/watch?v=DKsFKPx84mc

User Image Stayinvest Posted - 1 week ago

$CGEN this is not Pfizer

User Image Stayinvest Posted - 1 week ago

$CGEN this are therapies for cancer not vaccines. This therapies may save lives at some point

User Image Stayinvest Posted - 1 week ago

$CGEN thank you Cgen for killing my portobello. Still have you anyways

User Image Capn1diot Posted - 1 week ago

$CGEN I think all health stocks are getting battered with the appointment of RFK Jr.

User Image RachelGreene1 Posted - 1 week ago

$CGEN Hey, hey. I am able to speak whale!

User Image Stayinvest Posted - 1 week ago

$CGEN not nice Compugen, we all trust you

User Image HuntingBenjmins Posted - 1 week ago

$CGEN

User Image Capn1diot Posted - 1 week ago

$CGEN well this sucks

User Image Capn1diot Posted - 1 week ago

$CGEN I’m going into panic mode is this drops further tomorrow

User Image Stayinvest Posted - 1 week ago

$CGEN

User Image RachelGreene1 Posted - 1 week ago

$CGEN It will be a wonderful Christmas for me.

User Image RachelGreene1 Posted - 1 week ago

$CGEN

User Image HuntingBenjmins Posted - 1 week ago

$CGEN That, my friends, was the breaking of a very solid support at $1.50. CGEN for as solid as they are needs to put out some mind blowing positive news.

User Image HuntingBenjmins Posted - 1 week ago

$CGEN uggggg…

User Image RachelGreene1 Posted - 1 week ago

$CGEN It may sound strange, but I feel that this company is very strong. 4 is not the top of the mountain.

User Image HuntingBenjmins Posted - 1 week ago

$CGEN Now we need the algos to do their job….

User Image HuntingBenjmins Posted - 1 week ago

$CGEN I’m not sure who the Dr was that was explaining all of the positive things that they were seeing in their trials but he was super enthusiastic with what he’s seen. No debt, tons of money, more money coming, great partnerships. Great company!

User Image RachelGreene1 Posted - 1 week ago

$CGEN

User Image Capn1diot Posted - 1 week ago

$CGEN this is just painful. I usually don't budge on my portfolio allocation, but I think I will make an exception for these prices, but trust me, I'm very frustrated with this price action after the earnings.

User Image DirkInvest Posted - 1 week ago

$CGEN 140 million market cap, for a company with 113 million in cash, no debts and making a small profit? Future milestones bonusses with >1 billion in potential, plus high single ditit/low double digit royalties on the Gilead partnered program and mid single digit royalties to the Astrazenica partnered program, where they expect >5 billion in potential annual peak sales. The price here is just too good to be true. Sure most of the programs take time, and nobody likes waiting. But if you hold this stock for another 5 years, the share price is not going to be this cheap.

User Image Dombak Posted - 1 week ago

$CGEN small caps are almost always subject to price manipulation. The fundamentals are strong here, it's just a question of patience.

User Image Fuzzywhiteduck Posted - 1 week ago

$CGEN they only have to pay for the Phase 1 study for the GILD partnership. After that GILD takes over if they want to move forward. They can get up to around $800 million in milestones along the way plus high single digit to low double digit tiered royalties. Hopefully, if the share price keeps drifting down, they'll have some extra cash for a buy back program to keep it over $1.

Analyst Ratings
Truist Securities Buy May 21, 24
Truist Securities Buy Mar 8, 24
Stifel Buy Dec 19, 23
Truist Securities Buy Aug 23, 23
EF Hutton Buy Aug 7, 23
EF Hutton Buy Jun 6, 23
EF Hutton Buy May 26, 23
EF Hutton Buy May 24, 23
Oppenheimer Outperform May 16, 23